4.3 Article

Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine

期刊

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2020.102727

关键词

Relapsing remitting multiple sclerosis; Cladribine; Memory B cells; Hyperrepopulation; Immune phenotyping; Disease activity

向作者/读者索取更多资源

The study reported differences in the immune phenotype of a patient with disease activity during cladribine treatment compared to patients without disease activity, and discussed possible causes for these deviations as caveats regarding treatment sequelae. Both the case and controls showed similar reductions in memory B cells in response to cladribine, but the case exhibited accelerated repopulation dynamics of naive B cells with almost 3-fold hyperrepopulation compared to baseline levels. Additionally, the case had lower pre-treatment levels of CD4+ and CD8+ T cells and memory B cells compared to controls.
Background: Recent data support a key role of B cells in the pathogenesis of multiple sclerosis. Due to the pronounced effect of cladribine on memory B cells, we initiated an immune phenotyping study, which included monitoring of memory B cells of patients newly assigned to this treatment option. A patient with ongoing disease activity in the first year of cladribine after a long-standing fingolimod treatment caught our attention. Objective: To report about differences in the immune phenotype of the case compared to patients without disease activity and to discuss possible causes for the deviations as caveats regarding treatment sequelae. Methods: Clinical data and immune phenotyping data collected at baseline (before treatment) and after three, six and ten/twelve months after cladribine initiation were compared between our case and six patients with a stable disease course (controls). Results: Both, the case and controls showed similar reductions of memory B cells in response to cladribine. The case however, showed an accelerated repopulation dynamic of n & auml;ve B cells with an almost 3-fold hyperrepopulation compared to baseline levels, and lower pre-treatment levels of CD4+ and CD8+ T cells and memory B cells compared to controls. Conclusion: We propose a prolonged pre-treatment with fingolimod as possible cause for the lack of response to cladribine. Autoreactive cells sequestrated within lymph nodes may have evaded cladribine depletion on top of a delay of recirculating regulatory T cells. In addition, we want to raise awareness of the importance of monitoring T and B cells for bridging the current lack of evidence regarding sequencing therapies in the real life setting.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据